Corneal light scattering after CXL gives distinctive spatial and temporal profiles

Article

The spatial distribution and temporal profiles of corneal light scattering after corneal collagen crosslinking (CXL) are distinctive in keratoconus patients.

The spatial distribution and temporal profiles of corneal light scattering after corneal collagen crosslinking (CXL) are distinctive in keratoconus patients, states a study published by the Journal of Cataract and Refractive Surgery.

A team led by Dr Anders Behndig, Department of Clinical Sciences and Ophthalmology, Umeå University, Sweden, included 11 eyes in a case series of 11 keratoconus patients. All eyes were examined with Scheimpflug photography pre-CXL and 1 and 5 months post-CXL. Corneal light scattering was recorded throughout corneal thickness at 8 measurement points 0.0 to 3.0mm from the central cornea.

After CXL, central corneal light scattering increased significantly after 1 month. Corneal light scattering decreased after 6 months but stayed higher than pre-CXL values.

Light scattering at 1 month was more defined in the superficial stroma and gradually reduced to zero at 240μm depth. It was found that corneal light scattering was greater at the corneal centre. The second peak of light scattering occurred 6 months postoperatively between 240μm and 340μm depth.It was also concluded that Scheimpflug photography is useful for corneal light scattering.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.